Turning Point Therapeutics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics or view top-rated stocks.

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) released its quarterly earnings results on Sunday, February, 28th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by $0.08.
View Turning Point Therapeutics' earnings history.

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TPTX stock has increased by 154.3% and is now trading at $103.09.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 12 month price objectives for Turning Point Therapeutics' shares. Their forecasts range from $127.00 to $190.00. On average, they anticipate Turning Point Therapeutics' stock price to reach $153.57 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Turning Point Therapeutics include Horizon Therapeutics Public (HZNP), UCB (UCBJF), Genmab A/S (GNMSF), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), CureVac (CVAC), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Grifols (GRFS) and Dr. Reddy's Laboratories (RDY).
View all of TPTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (12.90%), BlackRock Inc. (6.55%), Price T Rowe Associates Inc. MD (5.28%), Lord Abbett & CO. LLC (2.74%), Alliancebernstein L.P. (1.96%) and Jennison Associates LLC (1.73%). Company insiders that own Turning Point Therapeutics stock include Annette North, Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Mohammad Hirmand, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., FMR LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Matthews International Capital Management LLC, Handelsbanken Fonder AB, Castleark Management LLC, and Aviva PLC. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mohammad Hirmand, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or view top insider-selling stocks.

TPTX stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, BlackRock Inc., Norges Bank, Credit Suisse AG, Candriam Luxembourg S.C.A., Jennison Associates LLC, and Federated Hermes Inc.. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or or view top insider-buying stocks.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TPTX stock can currently be purchased for approximately $103.09.

Turning Point Therapeutics has a market capitalization of $4.97 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis.

Turning Point Therapeutics employs 130 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]